INTRODUCTION
Therapy related acute myeloid leukaemia (t-AML) is a well-recognized clinical entity occurring as a complication after chemo and/ or radiation therapy administered for a prior neoplastic or non-neoplastic disease . t-AML accounts for 5% (2-10%) of all acute myeloid leukaemia (AML) cases. It is characterised by pancytopenia, multilineage dysplasia, high frequency of unfavourable cytogenetic findings and short survival [1, 10, 18, [21] [22] [23] [24] [25] [26] [27] [28] .
Two subsets of t-AML are generally recognized. The most common, classical t-AML occurs 5-10 years following exposure to alkylating agents and/or ionizing radiation. Patients often present with therapy related myelodysplastic syndrome (t-MDS) and unbalanced chromosomal abnormalities frequently of complex nature and involving chromosomes 5 and/or 7 [1] . The second category of t-AML encompassing 20-30% of patients has a latency period of about 1-5 years and follows the treatment with topoisomerase inhibitors (epipodophylotoxins, doxorubicin, mitoxantrone). Most patients in this subset present with overt AML, without t-MDS phase and with balanced chromosomal translocations [1] .
OBJECTIVE
The aim of this study was to analyse retrospectively clinical, cytological and cytogenetic features of t-AML patients, and their impact on survival.
METHODS

Patients
This retrospective series consists of 17 patients with t-AML (eight males and nine females; median age 59 years) among 730 consecutive AML patients seen at the Clinic of Haematology, Clinical Centre of Serbia, Belgrade, over a 7-year period (Table 1) .
Bone marrow sampling
Following informed consent, bone marrow (BM) cells were collected by aspiration from the sternal manubrium using a standard needle and 20 ml syringe with heparin anticoagulation. The BM aspirations underwent cytochemical and cytogenetic study.
Morphology and cytochemistry
BM smears were stained with a May-Grünwald-Giemsa, peroxidase, Sudan black B, periodic acid-Schiff, α-naphthyl-butyrate-esterase and naphthol-AS-D-chloroacetate according to standard methods and classified according to the French-American-British (FAB) classification [6] . Two distinct observers evaluated myelodysplasia in BM smears according to the criteria by Bennett et al. [6] . Namely, at least 200 neutrophils and precursors, 200 erythroblasts and at least 30 megakaryocytes (Mk) were evaluated for dysplasia. The method by Esteinne [11] was applied for the categorization of dysplasia; dysplasia in 25-50% of erythroblasts and granulocytes/precursors were graded as moderate and as marked when ≥50% cells affected. Dysmegakaryocytopoiesis was defined as the presence of at least 50% of dysplastic megakaryocytes in BM.
Cytogenetic analysis
Chromosome preparation was carried out either directly or after a non-stimulated short-term culture of BM cells for 24-48 hours, according to HG banding methods [14, 20] . Karyotypes were designated according to the ISCN. Pre-treatment karyotype was categorized according to Grimvade [12] 
Statistical analysis
In addition to the standard methods of descriptive and analytical statistics (Cox's regression multifactorial analysis, Mann-Whitney U-test, Kruskal-Wallis unifactorial nonparametric variance analysis, Spearman's rank correlation, Student's t-test for independent samples), the standardized Greenwood's formula was used for the assessment of overall survival (OS) rates according to age, presence/ degree of BM dysplasia and cytogenetic risk.
RESULTS
Clinical findings, treatment and bone marrow findings
Relevant clinical and cytomorphological data of 17 t-AML patients are presented in Table 1 . The median time-to-t-AML between the primary diagnosis and t-AML was 72 months (range 9-336 months).
Marked (>50% dysplastic cells) and moderate (25-50% dysplastic cells) erythroid dysplasia was registered in 5/16 Dysplasia of the megakaryocytic (Mk) lineage (>50% dysplastic Mk) was present in 7/11 analysed patients. The most frequent dysplastic features were Mk with hypolobulated nuclei (9/11), Mk with small bead-like nuclei (8/11), micromegakaryocytes (5/11) and Mk with cleaved nuclei (2/11).
Cytogenetic analysis
Cytogenetic information was obtained for 14/17 patients, while chromosome abnormalities were registered in 10/14 evaluated patients (Table 2) .
Survival
We investigated the correlation of overall survival (OS) compared to age, time-to-t-AML, organomegaly, degree of erythroid lineage, granulocyte count, Mk dysplasia and cytogenetic category. A statistically significant correlation was found between probability of survival and age (Graph 1), degree of granulocytic dysplasia (Graph 2) and favourable karyotype (Graph 3). Cox's regression multifactorial analysis showed that favourable prognostic factors were <60 years (p=0.016) and higher degree of dysplasia in granulocytic lineage (p=0.034). Greenwood analysis also added to the aforestated two factors, younger age (Z=2.412) and higher dysplasia percentage in granulocytic lineage (Z=4.561), and the presence of favourable karyotype versus unfavourable karyotype (Z=2.739). At the same time the degree of dysplasia in both erythroid and megakaryocytic lineages was without prognostic relevance for OS in t-AML in our series.
Median OS of patients ≥60 years was 25 days, and 90 days among patients <60 years (Graph 1). The probability of OS at any time point was higher among younger patients, but the statistically significant difference between the groups was observed only at the time point of 30 days (Z=2.412; p<0.05). The median OS in the group with ≤50% dysplastic cells in granulocytic lineage was 25 days, compared to 45 days in patients with >50% dysplastic cells in granulocytic lineage (Z=4.561; p<0.01) (Graph 2). Whereas all patients with ≤50% dysplastic cells in granulocytic lineage died within two months, one subject with AML-M3 and >50% dysplastic cells in granulocytic lineage lived longer than 24 months (and is still alive). At the same time, dysplasia in both erythroid and megakaryocytic lineages was without prognostic relevance on OS in t-AML patients in our series.
The median OS in the patients with favourable karyotype was 90 days, compared to 23 days in patients with unfavourable karyotype (Graph 3). The probability of OS at any time point was higher among younger patients, but the statistically significant difference between the groups was observed only at the time point of 15 days to 60 days (Z=2.739; p<0.05).
DISCUSSION
The incidence of t-AML in our AML series of 2.3% in the period of 7 years was considerably lower than 13% previously reported by Haase et al. [12] , but similar to 2% reported by Michels et al. [18] . The median age of our patients was 59 years, which corresponds to the Pedersen-Bjergaard's data [21] . The average time-to-t-AML was 6 years, which is in agreement with previous studies [10, 21, 24] . Our study confirmed the published data suggesting that the majority of the patients had been previously exposed to alkylating drugs: cyclophosphamide (five patients), busulfan (four patients), procarbazine (three patients) and melphalan (two patients) [8, 21, 24] . Only four patients had received topoisomerase II inhibitors (etoposide or doxorubicin) along with alkylating agents. Such a distribution of our t-AML patients according to the prior cytostatic is similar to previous reports [3, 23] .
Besides the fact that t-AML risk is more often associated with chemotherapy according to some investigators, other state that the haematological malignancy risk is increased following radiotherapy for certain malignancies [29, 30, 31] . Radiotherapy in conjunction with chemotherapy additionally increases the risk of t-AML [32, 33] . Four of our 17 t-AML patients had been previously treated with radiotherapy, one receiving radiotherapy alone as the treatment for urinary bladder carcinoma, while the remaining three received combined radiotherapy and chemotherapy; one of them for myeloma and other two for Hodgkin's disease ( Table 1) .
The results of our study show that three-lineage myelodysplasia is a frequent finding in t-AML, as confirmed by others [10] .
Cytogenetic abnormalities were found in the majority of patients, which corresponds to other studies [10, 22] . Favourable, adverse and intermediate karyotype was registered in three, three and eight cases, respectively. Anomalies of chromosomes 5 and 7 were found in only 2/14 patients.
Comparable to other studies, OS of t-AML patients was 4.42 months (mean survival: 1.5-7 months) [10, 22] . The probability of survival was significantly lower in patients ≥60 years compared to patients <60 years. This is in accordance with the findings of other studies analysing the prognostic criteria in t-AML [10, 22] .
The presence of dysplasia of more than one cell lineage is considered a poor prognostic factor in t-AML, correlating with poor response to therapy, shorter remission duration and shorter OS [19, 22, 23] . In contrast, we revealed a statistically longer OS in the patients with granulocytic dysplasia, especially that of marked degree. This is probably the result of younger ages of the patients with pronounced dysplasia, as well as of the small sample. Our result resembles the data by Estienne who reported that AML, but not t-AML patients with favourable karyotype generally had dysplasia of granulocytic lineage [11] . All the three patients with favourable karyotype from our series had marked granulocytic dysplasia, which is in agreement with Estienne's report. The degree of erythroid and Mk dysplasia, in our study, as well as in other studies, failed to show impact on OS [9, 11] .
Furthermore, patients with favourable karyotype had a significantly longer OS compared to unfavourable karyotype, which is in agreement with other authors' findings [16, 20, 26, 28] . Likewise, the shortest 25-day median OS was registered in patients with unfavourable karyotype compared with median survival of 80 days in patients with favourable karyotype. This result parallels those in the literature [20, 26] .
CONCLUSION
It must be taken into account that t-AML is regarded as an entity of poor prognosis and is to be treated as highrisk AML. However, due to the progress in elucidating the impact of cytogenetic and molecular markers for the prognosis and treatment outcome, the entity of t-AML may be as heterogeneous as de novo AML. Thus, a scoring system encompassing at least age, cytogenetics and granulocytic dysplasia is needed to subdivide this entity.
